CN1037267C - 制备三取代四氢呋喃衍生物的方法 - Google Patents

制备三取代四氢呋喃衍生物的方法 Download PDF

Info

Publication number
CN1037267C
CN1037267C CN92113399A CN92113399A CN1037267C CN 1037267 C CN1037267 C CN 1037267C CN 92113399 A CN92113399 A CN 92113399A CN 92113399 A CN92113399 A CN 92113399A CN 1037267 C CN1037267 C CN 1037267C
Authority
CN
China
Prior art keywords
compound
triazol
formula
phenyl
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92113399A
Other languages
English (en)
Chinese (zh)
Other versions
CN1073944A (zh
Inventor
A·K·沙森纳
V·M·吉里扎瓦拉汉
A·K·冈古利
R·G·洛维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1073944A publication Critical patent/CN1073944A/zh
Application granted granted Critical
Publication of CN1037267C publication Critical patent/CN1037267C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN92113399A 1991-10-30 1992-10-29 制备三取代四氢呋喃衍生物的方法 Expired - Fee Related CN1037267C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78535791A 1991-10-30 1991-10-30
US785,357 1991-10-30
US90726292A 1992-07-01 1992-07-01
US907,262 1992-07-01

Publications (2)

Publication Number Publication Date
CN1073944A CN1073944A (zh) 1993-07-07
CN1037267C true CN1037267C (zh) 1998-02-04

Family

ID=27120397

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92113399A Expired - Fee Related CN1037267C (zh) 1991-10-30 1992-10-29 制备三取代四氢呋喃衍生物的方法

Country Status (22)

Country Link
EP (2) EP0610377B1 (enExample)
JP (1) JP3210017B2 (enExample)
CN (1) CN1037267C (enExample)
AT (1) ATE198888T1 (enExample)
AU (1) AU665218B2 (enExample)
CA (1) CA2122270C (enExample)
CZ (1) CZ102794A3 (enExample)
DE (1) DE69231661T2 (enExample)
ES (1) ES2153364T3 (enExample)
FI (1) FI941986A0 (enExample)
HR (1) HRP921145A2 (enExample)
HU (1) HUT70742A (enExample)
IL (1) IL103558A0 (enExample)
MX (1) MX9206222A (enExample)
MY (1) MY109529A (enExample)
NO (1) NO941589L (enExample)
NZ (1) NZ244910A (enExample)
SG (1) SG42920A1 (enExample)
SI (1) SI9200285A (enExample)
SK (1) SK48894A3 (enExample)
WO (1) WO1993009114A1 (enExample)
YU (1) YU94792A (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403937A (en) * 1993-04-30 1995-04-04 Schering Corporation Process for preparing intermediates for the synthesis of antifungal agents
US5349099A (en) * 1993-12-13 1994-09-20 Schering Corporation Process for preparing intermediates for the synthesis of antifungal agents
US5693626A (en) * 1993-12-21 1997-12-02 Schering Corporation Tetrahydrofuran antifungals
AU681753B2 (en) * 1993-12-21 1997-09-04 Merck Sharp & Dohme Corp. Tetrahydrofuran antifungals
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5714490A (en) * 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
US5703236A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
US5710154A (en) * 1993-12-21 1998-01-20 Schering Corporation Tetrahydrofuran antifungals
PT741737E (pt) * 1994-01-24 2000-04-28 Janssen Pharmaceutica Nv Antifungicos do tipo azole soluveis em agua
CN1126987A (zh) * 1994-04-19 1996-07-17 钟渊化学工业株式会社 三唑衍生物的制造方法
US5442093A (en) * 1994-05-09 1995-08-15 Schering Corporation Process for preparing intermediates for the synthesis of antifungal agents
US5486625A (en) * 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
EP0725146A4 (en) * 1994-07-18 1998-12-23 Daicel Chem METHOD FOR PRODUCING OPTICALLY ACTIVE TRIAZOLE COMPOUNDS AND METHOD FOR RAZEMIZING OPTICALLY ACTIVE TRIAZOLE COMPOUNDS
US5616777A (en) * 1995-04-19 1997-04-01 Schering Corporation Chiral hydrazine derivatives
US5625064A (en) * 1995-04-19 1997-04-29 Schering Corporation Process for the preparation of triazolones
IL118464A (en) * 1995-06-02 2000-08-13 Schering Corp (2R-cis)-4-¬4-¬4-¬4¬¬-5-(2',4 dihalophenyl)-tetrahydro-5-(1-H-1,2,4,triazol-1-yl-methyl)furan-3-yl(methoxy¾phenyl¾-1-piperazinyl¬phenyl2,4,dihydro2¬(5)-1-ethyl-2-(5)hydroxy propyl¾-3H-1,2,4-triazol-3-one and pharmaceutical compositions comprising them
US5698557A (en) * 1995-06-19 1997-12-16 Schering Corporation Hydroxy-substituted antifungals
CA2224707A1 (en) * 1995-06-19 1997-01-03 Schering Corporation Tetrahydrofuran antifungals
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
TW593312B (en) * 1997-07-11 2004-06-21 Janssen Pharmaceutica Nv 2,4,4-trisubstituted-1,3-dioxolane antifungals
DE69822859T2 (de) * 1997-10-07 2005-01-27 Schering Corp. Krytallinischer fungizider polymorph
EA200401336A1 (ru) * 2002-04-12 2006-02-24 Ранбакси Лабораторис Лимитед Производные 2,2,4-тризамещенного тетрагидрофурана в качестве противогрибковых средств
WO2011144655A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Process for the preparation of chiral hydrazides
CA2798010C (en) 2010-05-19 2018-09-25 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
RU2585760C2 (ru) 2010-05-19 2016-06-10 Сандоз Аг Способ получения хиральных триазолонов
WO2011144656A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Preparation of posaconazole intermediates
CN108329303A (zh) 2011-06-16 2018-07-27 桑多斯股份公司 制备手性化合物的方法
AU2014274830B2 (en) * 2013-06-07 2017-11-09 The California Institute For Biomedical Research Small molecule inhibitors of fibrosis
CN106397417A (zh) * 2016-08-30 2017-02-15 甘肃皓天化学科技有限公司 用于制备泊沙康唑的中间体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173258A2 (de) * 1984-08-31 1986-03-05 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Substituierte 2-Phenyl-1,3-dioxolane
EP0283992A2 (en) * 1987-03-25 1988-09-28 Janssen Pharmaceutica N.V. 4-[4-[4-[4-[[2-(2,4-Difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyl]phenyl]triazolones
EP0402989A2 (en) * 1989-06-09 1990-12-19 Janssen Pharmaceutica N.V. Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5006513A (en) 1987-11-09 1991-04-09 Miles Inc. Antimycotic compositions of nikkomycin compounds and azole antimycotica
JPH0717634B2 (ja) * 1987-11-20 1995-03-01 シェリング・コーポレーション トリ‐およびテトラ‐置換‐オキセタンおよびテトラヒドロフランおよびその中間体
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173258A2 (de) * 1984-08-31 1986-03-05 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Substituierte 2-Phenyl-1,3-dioxolane
EP0283992A2 (en) * 1987-03-25 1988-09-28 Janssen Pharmaceutica N.V. 4-[4-[4-[4-[[2-(2,4-Difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyl]phenyl]triazolones
EP0402989A2 (en) * 1989-06-09 1990-12-19 Janssen Pharmaceutica N.V. Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones

Also Published As

Publication number Publication date
EP0610377A1 (en) 1994-08-17
CN1073944A (zh) 1993-07-07
FI941986A7 (fi) 1994-04-29
SG42920A1 (en) 1997-10-17
AU2916992A (en) 1993-06-07
NO941589L (enExample) 1994-06-23
HU9401256D0 (en) 1994-08-29
DE69231661T2 (de) 2001-08-02
CA2122270A1 (en) 1993-05-13
JP3210017B2 (ja) 2001-09-17
FI941986A0 (fi) 1994-04-29
ES2153364T3 (es) 2001-03-01
IL103558A0 (en) 1993-03-15
EP0539938A1 (en) 1993-05-05
CA2122270C (en) 2006-05-23
DE69231661D1 (de) 2001-03-01
EP0610377B1 (en) 2001-01-24
NO941589D0 (enExample) 1994-04-29
YU94792A (sh) 1995-12-04
AU665218B2 (en) 1995-12-21
ATE198888T1 (de) 2001-02-15
MX9206222A (es) 1993-04-01
WO1993009114A1 (en) 1993-05-13
MY109529A (en) 1997-02-28
HRP921145A2 (en) 1994-08-31
SI9200285A (en) 1993-06-30
JPH07500605A (ja) 1995-01-19
NZ244910A (en) 1996-01-26
CZ102794A3 (en) 1995-03-15
SK48894A3 (en) 1995-02-08
HUT70742A (en) 1995-10-30

Similar Documents

Publication Publication Date Title
CN1037267C (zh) 制备三取代四氢呋喃衍生物的方法
CN1064685C (zh) 四氢呋喃抗真菌剂
CN1078210C (zh) 水溶性吡咯系杀真菌剂
CN1085213C (zh) 用于治疗的三唑衍生物
CN1073109C (zh) 四氢呋喃杀真菌剂
CN1251098A (zh) 吡咯化合物,其制备及其用途
CN1137118C (zh) 用作广效性抗菌剂的水溶性唑类(一)
CN1026984C (zh) 偏端霉素衍生物的制备方法
CN1349524A (zh) 血管紧张肽原酶抑制剂
CN1126473A (zh) 化学组合物
CN1025193C (zh) 抗真菌用的唑酮类衍生物的制备方法
CN1210857A (zh) 三唑衍生物及其盐
CN1182739A (zh) N－苄基唑鎓衍生物
CN1181079A (zh) 作为阿朴脂蛋白－b合成抑制剂的新型三唑酮
CN1112113A (zh) 新的三唑化合物及其制备方法和用途
CN1082050C (zh) 用于人和兽医的具有抗真菌活性的唑类化合物
WO1997000248A1 (en) Hydroxyalkyl-substituted triazolones antifungals
JPH10231296A (ja) テトラヒドロフラン抗真菌剤
US5698557A (en) Hydroxy-substituted antifungals
PL170743B1 (pl) Sposób wytwarzania trójpodstawionego tetrahydrofuranowego związku
CN1628119A (zh) 作为抗真菌剂的2,2,4－三取代的四氢呋喃衍生物
HK1018273A (en) Triazole derivative or salt thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee